| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/05/2002 | CA2367001A1 The method for production of egg containing anti-e.coli igy and anti-helicobacter pylori igy and anti-salmonella enteritidis igy and anti-salmonella typhimurium igy simultaneously, and egg, yolk, yogurt and ice cream containing specific igy for anti-e.coli, anti-helicobacter pylori, anti-salmonella enteritidis and anti-salmonella typhimurium |
| 07/04/2002 | WO2002052014A2 Efficient expression of plasmodium apical membrane antigen 1 in yeast cells |
| 07/04/2002 | WO2002052004A1 Gene involved in apoptosis regulation |
| 07/04/2002 | WO2002052002A2 Immunomodulatory polynucleotides and methods of using the same |
| 07/04/2002 | WO2002051994A2 Polypeptides |
| 07/04/2002 | WO2002051871A2 Anti-cd28 antibody |
| 07/04/2002 | WO2002051865A2 Proteinic antigens inducing antibodies neutralising hiv virus |
| 07/04/2002 | WO2002051438A2 Use of repulsive guidance molecule (rgm) and its modulators |
| 07/04/2002 | WO2002051437A1 Induction of tolerance |
| 07/04/2002 | WO2002051430A2 Methods of modulating toll-related receptor (trr) signaling |
| 07/04/2002 | WO2002051254A1 Method of sterilizing antibody-containing milk and products containing sterilized antibody-containing milk |
| 07/04/2002 | WO2002051237A2 Helicobacter proteins, nucleic acids and uses thereof |
| 07/04/2002 | WO2002051233A2 Universal antimicrobial treatment |
| 07/04/2002 | WO2002033100A3 Regulation of human adenylate cyclase, type iv |
| 07/04/2002 | WO2002030351A3 Improvement of graft acceptance through manipulation of thymic regeneration |
| 07/04/2002 | WO2002004953A8 Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers |
| 07/04/2002 | WO2002002139A3 Methods and composition for oral vaccination |
| 07/04/2002 | WO2001089557A3 Methods for preventing strokes by inducing tolerance to e-selectin |
| 07/04/2002 | WO2001078779A3 Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease |
| 07/04/2002 | WO2001078768A3 Targeted vaccine delivery systems |
| 07/04/2002 | WO2001070266A3 Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2 |
| 07/04/2002 | WO2001070265A3 Lipopeptide adjuvants |
| 07/04/2002 | WO2001064886A3 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| 07/04/2002 | WO2001057207A3 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 07/04/2002 | WO2001046420A8 Il-17 and il-17r homologous polypeptides and therapeutic uses thereof |
| 07/04/2002 | WO2001035811A9 Methods of diagnosing and determining prognosis of breast cancer |
| 07/04/2002 | WO2001032189A9 Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
| 07/04/2002 | WO2000069897A9 Modulation of glgf motif (dhr/pdz) containing proteins interaction with cd3n in t lymphocytes |
| 07/04/2002 | WO2000068242A9 Collagen-binding proteins from enterococcal bacteria |
| 07/04/2002 | WO2000022430A9 Neisseria genomic sequences and methods of their use |
| 07/04/2002 | US20020086984 Nucleotide sequences coding preferential polypeptides for use in the detection, prevention and treatment of microorganismal infection |
| 07/04/2002 | US20020086981 Method of isolation of regulated virulence determinants from bacterial pathogens |
| 07/04/2002 | US20020086978 Specific binding agents |
| 07/04/2002 | US20020086974 Protein for use in the prevention of worm parasitic infection in animals; for use in veterinary medicine |
| 07/04/2002 | US20020086841 Naked DNA construct encoding a cytokine selected from macrophage inflammatory protein-1 alpha, monocyte chemoattractant protein 1, and tumor necrosis factor-alpha, linked to a viral transcription control sequence, and carrier |
| 07/04/2002 | US20020086839 Inhibitors of DNA immunostimulatory sequence activity |
| 07/04/2002 | US20020086837 Acne vaccine |
| 07/04/2002 | US20020086827 RANK (receptor activator of neurotrophic factor-kappa B) polypeptides; immunoregulatory activity |
| 07/04/2002 | US20020086826 Antibodies against ligand for receptor activator of NF-kB |
| 07/04/2002 | US20020086813 Mutants of streptococcal toxin a and methods of use |
| 07/04/2002 | US20020086421 Tumor cells with increased immunogenicity and uses therefor |
| 07/04/2002 | US20020086414 Novel ctla4/cd28 ligands and uses therefor |
| 07/04/2002 | US20020086413 LktA deletion mutant of P. haemolytica |
| 07/04/2002 | US20020086403 Polypeptide for use in the treatment and prevention of viral infections and cancer |
| 07/04/2002 | US20020086385 Nucleotide sequences coding enzyymatic polypeptide for use in prevention of bacterial infection; bactericides |
| 07/04/2002 | US20020086382 Nucleotide sequences coding membrane protein for use in the prevention and treatment of autoimmune diseases |
| 07/04/2002 | US20020086360 Polypeptide for use in treatment of congestive heart failure, ischaemic heart defects, arrhytmias, cardioiomyopathy and stroke |
| 07/04/2002 | US20020086352 Methods for expressing endostatin protein |
| 07/04/2002 | US20020086349 Nucleic acid molecules which code proteins which mediate the adhesion of neisseria cells to human cells |
| 07/04/2002 | US20020086348 Tolerogenic fragments of natural allergens |
| 07/04/2002 | US20020086332 Method of reducing bacterial proliferation |
| 07/04/2002 | US20020086316 Reagents and methods useful for detecting diseases of the prostate |
| 07/04/2002 | US20020086304 Method of isolation of regulated virulence determinants from bacterial pathogens |
| 07/04/2002 | US20020086285 Variant of LAV viruses |
| 07/04/2002 | US20020086284 Determining sensitivity of a cell to reovirus infection; obtain cells, monitor ras protein signaling, consistent signaling indicates sensitivity to reovirus infection |
| 07/04/2002 | US20020086283 Immunogen |
| 07/04/2002 | US20020086276 Immunotherapeutic methods for extracorporeal modulation of CD36 and its ligands |
| 07/04/2002 | US20020086037 For use in therapy of bacterial infections, cancer; in vaccines |
| 07/04/2002 | US20020086036 Therapy of hyperhidrosis (excessive sweating) in a mammal, by locally administering a drug particle to an affected skin area without using a needle |
| 07/04/2002 | US20020086035 Vaccines for therapy of immunomodulatory or immunoregulatory diseases |
| 07/04/2002 | US20020086034 Compositions and methods for treating viral infections |
| 07/04/2002 | US20020086033 Pestivirus mutants and vaccines containing the same |
| 07/04/2002 | US20020086032 Administering immunogenic dose of attenuated bacteria comprising altered DNA adenine methylase (Dam) activity relative to a wild-type bacteria for generating immune response and produce antibodies |
| 07/04/2002 | US20020086031 Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another pathogen |
| 07/04/2002 | US20020086030 Preparations and methods for the treatment of t cell mediated diseases |
| 07/04/2002 | US20020086028 Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof |
| 07/04/2002 | US20020086027 Exposure of T cells or animals being immunized to the commonly used phosphodiesterase inhibitor drug, pentoxifylline during immune priming. |
| 07/04/2002 | US20020086026 Novel vaccine development |
| 07/04/2002 | US20020086025 Antibodies that bind to alpha2-antiplasmin crosslinked to fibrin which do not inhibit plasma alpha2-antiplasmin |
| 07/04/2002 | US20020086024 RatB polypeptides and DNA (RNA) encoding ratB polypeptides producing such polypeptides by recombinant techniques; utilizing ratB polypeptides to screen for antibacterial compounds. |
| 07/04/2002 | US20020086020 Method for improving the half-life of soluble viral receptors on mucosal membranes |
| 07/04/2002 | US20020086019 Use of polypeptides or nucleic acids for the diagnosis or treatment of skin disorders and wound healing and for the identification of pharmacologically active substances |
| 07/04/2002 | US20020086018 Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI |
| 07/04/2002 | US20020086017 GA binding protein and neurite derived growth factors for use in the treatment of muscular dystrophy |
| 07/04/2002 | US20020086015 Compositions and methods for promoting nerve regeneration |
| 07/04/2002 | US20020086012 Costimulation of t-cell proliferation by a chimeric bispecific costimulatory protein |
| 07/04/2002 | US20020086011 Administering an effective amount of an OX-2 protein or a nucleic acid encoding an OX-2 protein; use to suppress an immune response and to prevent or treat autoimmune disease, especially arthritis. |
| 07/04/2002 | US20020086008 Human chitinase, its recombinant production, its use for decomposing chitin, its use in therapy or prophylaxis against infection diseases |
| 07/04/2002 | US20020086005 Tolerizing allografts of pluripotent stem cells |
| 07/04/2002 | US20020086004 Especially wherein said angiogenic factor is an endothelial cell growth factor chosen from the FGF family of growth factors and the VEGF family of growth factors. |
| 07/04/2002 | US20020086003 Thymus reactivation, especially by administering hematopoietic stem cells |
| 07/04/2002 | US20020086002 Hematopoietic stem cell gene therapy |
| 07/04/2002 | US20020086001 Normalization of defective T cell responsiveness through manipulation of thymic regeneration |
| 07/04/2002 | US20020086000 Stimulation of thymus for vaccination development |
| 07/04/2002 | US20020085999 Marek's disease virus genes and their use in vaccines for protection against marek's disease |
| 07/04/2002 | US20020085998 Breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, and T cells that are specific for cells expressing such polypeptides. |
| 07/04/2002 | US20020085997 Tumor cells at least some of which contain at least one MHC-I-haplotype of the patient on the cell surface, and which are charged with one or more peptides binding to the MHC-I molecule |
| 07/04/2002 | US20020085996 Can be administered before, at the same time as, or after the transplant. |
| 07/04/2002 | US20020085993 Antigens of the invention may be used as immunogens for vaccines or for the treatment of autoimmune diseases such as juvenile diabetes and multiple sclerosis. |
| 07/04/2002 | US20020084187 Using Gradiflow electrophoresis technology for macromolecule separation which utilises tangential flow across the membrane |
| 07/04/2002 | CA2782510A1 Polypeptides |
| 07/04/2002 | CA2432542A1 Methods of modulating toll-related receptor (trr) signaling |
| 07/04/2002 | CA2432214A1 Gene involved in apoptosis regulation |
| 07/04/2002 | CA2431835A1 Induction of tolerance |
| 07/04/2002 | CA2430930A1 Helicobacter proteins, nucleic acids and uses thereof |
| 07/04/2002 | CA2430691A1 Immunomodulatory polynucleotides and methods of using the same |
| 07/03/2002 | EP1219711A2 Lawsonia intracellularis vaccine |
| 07/03/2002 | EP1219638A2 G-protein coupled receptors having homology to the P2Y purinoreceptor 1 (P2Y1) |
| 07/03/2002 | EP1219635A2 Chlamydia pneumoniae antigenes |
| 07/03/2002 | EP1219301A1 Vaccines containing hybrid polypeptides consisting of at least two different allergenic proteins |